Abstract

Aims/hypothesis

Among white European children developing type 1 diabetes, the otherwise common HLA haplotype DR15-DQ6 is rare, and highly protective. Adult-onset type 1 diabetes is now known to represent more overall cases than childhood onset, but it is not known whether DR15-DQ6 is protective in older-adult-onset type 1 diabetes. We sought to quantify DR15-DQ6 protection against type 1 diabetes as age of onset increased.

Methods

In two independent cohorts we assessed the proportion of type 1 diabetes cases presenting through the first 50 years of life with DR15-DQ6, compared with population controls. In the After Diabetes Diagnosis Research Support System-2 (ADDRESS-2) cohort (n = 1458) clinician-diagnosed type 1 diabetes was confirmed by positivity for one or more islet-specific autoantibodies. In UK Biobank (n = 2502), we estimated type 1 diabetes incidence rates relative to baseline HLA risk for each HLA group using Poisson regression. Analyses were restricted to white Europeans and were performed in three groups according to age at type 1 diabetes onset: 0–18 years, 19–30 years and 31–50 years.

Results

DR15-DQ6 was protective against type 1 diabetes through to age 50 years (OR < 1 for each age group, all p < 0.001). The following ORs for type 1 diabetes, relative to a neutral HLA genotype, were observed in ADDRESS-2: age 5–18 years OR 0.16 (95% CI 0.08, 0.31); age 19–30 years OR 0.10 (0.04, 0.23); and age 31–50 years OR 0.37 (0.21, 0.68). DR15-DQ6 also remained highly protective at all ages in UK Biobank. Without DR15-DQ6, the presence of major type 1 diabetes high-risk haplotype (either DR3-DQ2 or DR4-DQ8) was associated with increased risk of type 1 diabetes.

Conclusions/interpretation

HLA DR15-DQ6 confers dominant protection from type 1 diabetes across the first five decades of life.

Details

Title
DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life
Author
Thomas, Nicholas J 1   VIAFID ORCID Logo  ; Dennis, John M 2   VIAFID ORCID Logo  ; Sharp, Seth A 2   VIAFID ORCID Logo  ; Kaur Akaal 3 ; Misra Shivani 3   VIAFID ORCID Logo  ; Walkey, Helen C 3   VIAFID ORCID Logo  ; Johnston, Desmond G 3   VIAFID ORCID Logo  ; Oliver, Nick S 3   VIAFID ORCID Logo  ; Hagopian, William A 4   VIAFID ORCID Logo  ; Weedon, Michael N 2   VIAFID ORCID Logo  ; Patel, Kashyap A 1   VIAFID ORCID Logo  ; Oram, Richard A 5   VIAFID ORCID Logo 

 University of Exeter Medical School, Institute of Biomedical and Clinical Science, Exeter, UK (GRID:grid.8391.3) (ISNI:0000 0004 1936 8024); Royal Devon and Exeter NHS Foundation Trust, Department of Diabetes and Endocrinology, Exeter, UK (GRID:grid.419309.6) (ISNI:0000 0004 0495 6261) 
 University of Exeter Medical School, Institute of Biomedical and Clinical Science, Exeter, UK (GRID:grid.8391.3) (ISNI:0000 0004 1936 8024) 
 Imperial College, Faculty of Medicine, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111) 
 Pacific Northwest Research Institute, Seattle, USA (GRID:grid.280838.9) (ISNI:0000 0000 9212 4713) 
 University of Exeter Medical School, Institute of Biomedical and Clinical Science, Exeter, UK (GRID:grid.8391.3) (ISNI:0000 0004 1936 8024); Royal Devon and Exeter NHS Foundation Trust, Renal Department, Exeter, UK (GRID:grid.419309.6) (ISNI:0000 0004 0495 6261) 
Pages
2258-2265
Publication year
2021
Publication date
Oct 2021
Publisher
Springer Nature B.V.
ISSN
0012186X
e-ISSN
14320428
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2569870234
Copyright
© The Author(s) 2021. corrected publication 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.